Study: NCT04421378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose and Formulation: 20 milligram (mg); Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide (TMZ)
Description: Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Dose strength and Formulation: 5, 20, 100, 140, 180, or 250 mg; Capsule Route of Administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine (CCNU)
Description: Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU)
Description: Dose and Formulation: 10, 40, or 100 mg; Capsule Route of Administration: Oral

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fractionated Radiation therapy (RT)
Description: Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fractionated Radiation therapy (RT)
Description: Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Fractionated Radiation therapy (RT)
Description: Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard Fractionated Radiation therapy (RT)
Description: Radiation Therapy Oncology Group (RTOG) or European Organisation for Research and Treatment of Cancer (EORTC) methodologies of approximately 60 Gy in 30 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dose and Formulation: 10 mg/kg; Route of Administration: Intravenous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTField
Description: Dose and Formulation: 200 kHz ≥18h/day; Route of administration: Scalp application of transducer arrays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carmustine
Description: Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Dose and Formulation: 150 or 200 mg/m\^2; Route of Administration: Intravenous